Imlygic
Imlygic ingredients
| Active ingredient | Strength |
|---|---|
| Talimogene Laherparepvec | 1000000 [PFU]/mL, 100000000 [PFU]/mL |
What Imlygic is used for
The FDA lists the approved uses on the official label (below). In the EU, talimogene laherparepvec is approved as Imlygic for:
Imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Imlygic
- Generic name
- Talimogene laherparepvec
- Made by
- Amgen Inc
- Forms
- Injection, Suspension
- Given
- Intralesional
- FDA approval
- Biologic licence (BLA) BLA125518
- On the US market since
- 2015
Official information
- Imlygic prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Talimogene laherparepvec)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Imlygic?
Imlygic (Talimogene laherparepvec) is a cancer medicine made by Amgen Inc, approved by the US FDA.
What are the ingredients of Imlygic?
Imlygic contains Talimogene Laherparepvec (1000000 [PFU]/mL, 100000000 [PFU]/mL).
Is Imlygic approved in Europe?
The same active substance is approved in the EU as Imlygic.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA